Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The global bipolar disorder treatment market attained a value of USD 5.3 billion in 2022. The market is expected to grow at a CAGR of 2.5% during the forecast period of 2023-2031 to attain a value of USD 6.7 billion by 2031. The growth of the market can be attributed to the rising cases of mental, sexual, and emotional abuse across the globe.
Bipolar disorder refers to a mental illness which is also known as manic depression. In this condition, the patient experiences extreme mood swings and goes through highs and lows of emotions. These mood swings can jeopardize the patients’ health by affecting their sleep cycle, energy levels, daily activities. It can also severely affect their ability to judgment, their behaviour, and the capacity of making any decision clearly. While some people experience these mood swings at repeated occasions, others do not experience major symptoms.
Bipolar disorder is a manageable condition if the patient manages to control and handle their mood swings, along with a little help from the physician, it always poses the threat to turn into severe depression, which can be fatal as the patient can become violent and even suicidal.
The condition can become worse if not taken care of within time, and this can be done by observing the symptoms in the patient. Some of the most common symptoms of the disease are as follows:
This report categorises the global bipolar disorder market into the following segmentations:
Market Breakup by Type
Market Breakup by Mechanism of Action
Market Breakup by Diagnosis Method
Bipolar Disorder Treatment Market Breakup by Treatment Method
Market Breakup by Treatment Channel
Market Breakup by Region
According to WHO, 40 million people across the world experienced bipolar disorder in 2019. The prevalence of mental disorders is rising at an alarming rate due to the rising stress among people. About 970 million people, that is one out of eight people, is suffering from some or the other mental disorder. The prevalence rate and incidence rate of the disorder is rising constantly across the globe. While treatment exists, the biggest problem is that the awareness about the treatment is extremely low, along with the restricted access to help and effective care.
While most of the people are gradually understanding the importance of addressing mental health issues, it is still considered as a taboo in many regions, which makes it difficult for the patients to ask for help, leading to more suicides.
The physician would first approach the non-pharmaceutical treatment by suggesting some exercised that can help the patient to relax and attain relief from some of the major symptoms of the condition.
The physician usually just prescribes medicines like mood stabilizers, antidepressants, second-generation (atypical) neuroleptics, also known as antipsychotics. Mood stabilizers include drugs with lithium or valproate content. These two can help restrict/prevent the episodes of mood swings or reduce their severity. Lithium also helps in decreasing the risk of suicide and suicidal thoughts. These drugs are also help induce sleep in insomniac patients for some time, till the time their pattern is regulated.
Psychotherapy is widely regarded as the most effective treatment as it helps the patient to talk about the emotions, thoughts, and behaviours. This helps them let loose of the build up that might have been there for years. The talk therapy helps the patients talk to their physicians without being worried about being judged or mistreated. This can help them get relief from majority of the symptoms as they are able to express their emotions in a much better way.
The psychotherapies have evolved drastically in the past few years due to the rising awareness about its importance among people. With the rising awareness about the importance of addressing mental health issues and the increased support from the government, the demand for psychotherapy is now rising at a rapid pace. This is propelling the bipolar disorder treatment market development. The major therapies include cognitive behavioural therapy, group therapy, vocational therapy interpersonal and social rhythm therapy.
The report gives an in-depth analysis of the key players involved in the bipolar disorder treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Type||
|Breakup by Mechanism of Action||
|Breakup by Diagnosis Method||
|Breakup by Treatment Method||
|Breakup by Treatment Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Bipolar Disorder Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Bipolar Disorder Treatment Market
6.1 Global Bipolar Disorder Treatment Market Overview
6.2 Global Bipolar Disorder Treatment Market Analysis
6.2.1 Market Overview
126.96.36.199 Global Bipolar Disorder Treatment Market Historical Value (2016-2022)
188.8.131.52 Global Bipolar Disorder Treatment Market Forecast Value (2023-2031)
6.3 Global Bipolar Disorder Treatment Market by Type
6.3.1 Market Overview
184.108.40.206 Bipolar I Disorder
220.127.116.11 Bipolar II Disorder
18.104.22.168 Cyclothymic Disorder
6.4 Global Bipolar Disorder Treatment Market by Mechanism of Action
6.4.1 Market Overview
22.214.171.124 Tricyclic Antidepressants
126.96.36.199 Monoamine Oxidase Inhibitors
188.8.131.52 Serotonin-Norepinephrine Reuptake Inhibitors
184.108.40.206 Selective Serotonin Reuptake Inhibitors
6.5 Global Bipolar Disorder Treatment Market by Diagnosis Method
6.5.1 Market Overview
220.127.116.11 Physical Exam
18.104.22.168 Psychiatric Assessment
22.214.171.124 Mood Charting
6.6 Global Bipolar Disorder Treatment Market by Treatment Method
6.6.1 Market Overview
126.96.36.199.1.2 Bright Light Therapy
188.8.131.52.1.3 Exercise Therapy
184.108.40.206.1.4 Sleep Deprivation
220.127.116.11.1.5 Vagus Nerve Stimulation
18.104.22.168.2.1 Mood Stabilizers
22.214.171.124.2.4 Adjunctive and Alternative Treatments
126.96.36.199.1.1 Cognitive Behavioural Therapy
188.8.131.52.1.2 Group Therapy
184.108.40.206.1.3 Interpersonal and Social Rhythm Therapy
220.127.116.11.1.4 Vocational Therapy
6.7 Global Bipolar Disorder Treatment Market by Treatment Channel
6.8 Global Bipolar Disorder Treatment Market by Region
6.8.1 Market Overview
18.104.22.168 North America
22.214.171.124.1 Historical Trend (2016-2022)
126.96.36.199.2 Forecast Trend (2023-2031)
188.8.131.52.1 Historical Trend (2016-2022)
184.108.40.206.2 Forecast Trend (2023-2031)
220.127.116.11 Asia Pacific
18.104.22.168.1 Historical Trend (2016-2022)
22.214.171.124.2 Forecast Trend (2023-2031)
126.96.36.199 Latin America
188.8.131.52.1 Historical Trend (2016-2022)
184.108.40.206.2 Forecast Trend (2023-2031)
220.127.116.11 Middle East and Africa
18.104.22.168.1 Historical Trend (2016-2022)
22.214.171.124.2 Forecast Trend (2023-2031)
7 North America Bipolar Disorder Treatment Market
7.1 United States of America
7.1.1 Historical Trend (2016-2022)
7.1.2 Forecast Trend (2023-2031)
7.2.1 Historical Trend (2016-2022)
7.2.2 Forecast Trend (2023-2031)
8 Europe Bipolar Disorder Treatment Market
8.1 United Kingdom
8.1.1 Historical Trend (2016-2022)
8.1.2 Forecast Trend (2023-2031)
8.2.1 Historical Trend (2016-2022)
8.2.2 Forecast Trend (2023-2031)
8.3.1 Historical Trend (2016-2022)
8.3.2 Forecast Trend (2023-2031)
8.4.1 Historical Trend (2016-2022)
8.4.2 Forecast Trend (2023-2031)
9 Asia Pacific Bipolar Disorder Treatment Market
9.1.1 Historical Trend (2016-2022)
9.1.2 Forecast Trend (2023-2031)
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
9.4.1 Historical Trend (2016-2022)
9.4.2 Forecast Trend (2023-2031)
9.5.1 Historical Trend (2016-2022)
9.5.2 Forecast Trend (2023-2031)
10 Latin America Bipolar Disorder Treatment Market
10.1.1 Historical Trend (2016-2022)
10.1.2 Forecast Trend (2023-2031)
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
11 Middle East and Africa Bipolar Disorder Treatment Market
11.1 Saudi Arabia
11.1.1 Historical Trend (2016-2022)
11.1.2 Forecast Trend (2023-2031)
11.2 United Arab Emirates
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 South Africa
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
12 Current Scenario Evaluation and Regulatory Framework
12.1 Emerging Therapies and Clinical Trials Synopsis
12.2 Patent Landscape
12.2.1 Patent Overview
126.96.36.199 Patent Status and Expiry
188.8.131.52 Timelines from Drug Development to Commercial Launch
184.108.40.206 New Drug Application
220.127.116.11.1 Documentation and Approval Process
12.3 Cost of Treatment
12.4 Regulatory Framework
12.4.1 Regulatory Overview
18.104.22.168 US FDA
22.214.171.124 EU EMA
126.96.36.199 INDIA CDSCO
188.8.131.52 JAPAN PMDA
13 Challenges and Unmet Needs
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop-Out Analysis
13.3 Awareness and Prevention Gaps
14 Global Bipolar Disorder Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 GlaxoSmithKline Plc.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2 Novartis International AG
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3 Takeda Pharmaceutical Industries Ltd.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4 Pfizer Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 Allergan Plc. (AbbVie Inc)
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6 AstraZeneca Plc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7 Bristol-Myers Squibb Co.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 Eli Lilly and Company
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9 Astellas Pharma Inc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.10 Johnson And Johnson Services, Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
16 Recommendations and Discussion
17 Global Bipolar Disorder Treatment Drugs Distribution Model (Additional Insight)
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Payment Methods (Additional Insight)
18.1 Government Funded
18.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The bipolar disorder treatment market attained a value of nearly USD 5.3 billion in 2022.
The market is projected to grow at a CAGR of 2.5% during the forecast period of 2023-2031.
The market is estimated to witness a healthy growth in the forecast period of 2023-2031 to reach USD 6.7 billion by 2031.
The growth of the market is driven by factors like rising prevalence of anxiety, ADHD, and other mental health issues.
The rising awareness about the importance of addressing mental health issues is driving the growth of the market.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The types of the disease can be categorised into bipolar I disorder, bipolar II disorder, and cyclothymic disorder.
The mechanism of action includes Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Benzodiazepines, Serotonin-Norepinephrine Reuptake Inhibitors, Beta-Blockers, and Selective Serotonin Reuptake Inhibitors, among others.
The diagnostic methods for the disease include physical exam, psychiatric assessment, and mood charting.
The treatment methods include physical therapy and psychotherapy. Physical therapy can be divided into non-pharmaceuticals and pharmaceutical treatment. Non-pharmaceuticals include acupuncture, bright light therapy, exercise therapy, sleep deprivation, and vagus nerve stimulation. Pharmaceuticals include mood stabilizers, antidepressants, antipsychotics, adjunctive and alternative treatments. Psychotherapy includes therapies like cognitive behavioural therapy, group therapy, interpersonal and social rhythm therapy, and vocational therapy.
The treatment channels in the market include public and private channels.
The key players in the market include GlaxoSmithKline Plc., Novartis International AG, Takeda Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc., Bristol-Myers Squibb Co., Eli Lilly and Company, Astellas Pharma Inc., Johnson and Johnson Services, Inc., and Allergan Plc. (AbbVie Inc).
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.